High levels of CD34^{+}CD38$^{low/-}$CD123^{+} blasts are predictive of an adverse outcome in acute myeloid leukemia: a *Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang* (GOELAMS) study

François Vergez,[1,2,§] Alexa S. Green,[3,4,§] Jerome Tamburini,[3,4,7] Jean-Emmanuel Sarry,[1] Baptiste Gaillard,[9] Pascale Cornillet-Lefebvre,[9] Melanie Pannetier,[3,4] Aymeric Neyret,[3,4] Nicolas Chapuis,[3,4] Norbert Ifrah,[10] François Dreyfus,[3,4,7] Stéphane Manenti,[1] Cecile Demur,[1,2] Eric Delabesse,[1,2] Catherine Lacombe,[3,4,8] Patrick Mayeux,[3,4] Didier Bouscary,[3,4,7] Christian Recher,[1,5,6§*] and Valerie Bardet[3,4,8,§*]

[1]INSERM, U1037, Cancer Research Center of Toulouse, Toulouse; [2]Laboratoire d'Hématologie, Toulouse; [3]Institut Cochin, Université Paris Descartes, Faculté de Médecine, CNRS (UMR8104), Paris; [4]Inserm, U1016, Paris, France; [5]Université Toulouse III Paul-Sabatier, Toulouse; [6]CHU Toulouse, Hôpital Purpan, Service d'Hématologie, Toulouse; [7]Service de Médecine Interne-UF d'Hématologie, Hôpital Cochin, AP-HP, Paris; [8]Service d'Hématologie Biologique, Hôpital Cochin, AP-HP, Paris; [9]Service d'Hématologie Biologique, CHU Robert Debré, Reims, and [10]Service d'Hématologie Clinique, CHU, Angers, France

Citation: Vergez F, Green AS, Tamburini J, Sarry J-E, Gaillard B, Cornillet-Lefebvre P, Pannetier M, Neyret A, Chapuis N, Ifrah N, Dreyfus F, Manenti S, Demur C, Delabesse E, Lacombe C, Mayeux P, Bouscary D, Recher C, and Bardet V. High levels of CD34^{+}CD38$^{low/-}$CD123^{+} blasts are predictive of an adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucémies Aiguës et Maladies du Sang *(GOELAMS) study. Haematologica 2011;96(12):1792-1798. doi:10.3324/haematol.2011.047894*

A



B



C

	SD	CV (%)
CD34+	1.67	3.45
CD38+	2.42	3.60
CD123+	2.48	3.29
CD34+CD38-	0.33	1.63
CD34+CD38-CD123+	0.72	5.94

Figure 1. (A) Comparison of CD34, CD38 and CD123 staining from fresh and frozen samples (n=5). (B) Comparison between the two flow cytometers (n=11 samples), percentage of CD34^{+}CD38^{-}CD123^{+} cells, (C) standard deviation (SD) and coefficient of variations (CV) of flow parameters.



Figure 2. Comparison of disease-free and overall survival in AML patients with adverse cytogenetics (n=19) according to the percentage of $CD34^{+}CD38^{low/-}CD123^{+}$ cells.



Figure 3. Usefulness of CD123 to differentiate normal and leukemic cells. (A) Comparison between percentages of $CD34^{+}CD38^{low/-}$ and $CD34^{+}CD38^{low/-}CD123^{+}$ cells in patients with less than 1% of $CD34^{+}CD38^{low/-}CD123^{+}$ cells. The amount of $CD34^{+}CD38^{low/-}CD123^{+}$ cells was significantly lower (median: 0.27% *versus* 0.80%, *P*=0.0003). Among the 40 patients who had less than 1% of $CD34^{+}$ $CD38^{low/-}CD123^{+}$ cells, 17 had more than 1% of $CD34^{+}CD38^{low/-}$ cells. No differences in survival were seen in patients with more or less than 1% of $CD34^{+}CD38^{low/-}$ cells. (B) Disease-free survival. (C) overall survival.